{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:08:06Z","timestamp":1791727686696,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.amepre.2018.09.020","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T03:06:40Z","timestamp":1545016000000},"page":"196-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6572-8658","authenticated-orcid":false,"given":"Ira L.","family":"Leeds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanthkumar","family":"Namasivayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assanatou","family":"Bamogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi","family":"Sankhla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winter M.","family":"Thayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.amepre.2018.09.020_bib0001","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"issue":"9580","key":"10.1016\/j.amepre.2018.09.020_bib0002","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.amepre.2018.09.020_bib0003","unstructured":"Centers for Disease Control and Prevention (CDC). Enhanced Meningococcal Disease Surveillance Report. www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report.pdf. Published 2016. Accessed April 23, 2018."},{"issue":"5","key":"10.1016\/j.amepre.2018.09.020_bib0004","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3201\/eid2305.161870","article-title":"Serogroup B meningococcal disease vaccine recommendations at a university, New Jersey, USA, 2016","volume":"23","author":"Soeters","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.amepre.2018.09.020_bib0005","unstructured":"Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for use of serogroup B meningococcal (MenB) vaccines in persons at increased risk for serogroup B meningococcal disease. www.cdc.gov\/vaccines\/acip\/recs\/grade\/mening-serogroup-b.html. Published 2015. Accessed April 24, 2018."},{"issue":"19","key":"10.1016\/j.amepre.2018.09.020_bib0006","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","article-title":"Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine\u2014Advisory Committee on Immunization Practices, 2016","volume":"66","author":"Patton","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amepre.2018.09.020_bib0007","unstructured":"Centers for Disease Control and Prevention (CDC). Vaccines for Children Program. www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/index.html. Published 2018. Accessed March 15, 2018."},{"key":"10.1016\/j.amepre.2018.09.020_bib0008","unstructured":"National Meningitis Association. Beyond the Science: Putting a Face on Meningococcal Disease. Fort Meyers, FL; National Meningitis Association. www.nmaus.org\/wp-content\/uploads\/2015\/02\/nma-beyond-the-science-report.pdf. Published 2015. Accessed September 27, 2018."},{"key":"10.1016\/j.amepre.2018.09.020_bib0009","unstructured":"Herzog K. Separate vaccine can protect against meningitis B strain. USA Today. http:\/\/college.usatoday.com\/2016\/08\/17\/separate-vaccine-can-protect-against-meningitis-b-strain\/. Published August 17, 2016. Accessed September 27, 2018."},{"issue":"10","key":"10.1016\/j.amepre.2018.09.020_bib0010","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2018.09.020_bib0011","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2017"},{"key":"10.1016\/j.amepre.2018.09.020_bib0012","unstructured":"Centers for Disease Control and Prevention (CDC). Guidance for the Evaluation and Public Health Management of Suspected Outbreak of Meningococcal Disease. Atlanta, GA: CDC. www.cdc.gov\/meningococcal\/downloads\/meningococcal-outbreak-guidance.pdf. Published 2017. Accessed September 27, 2018."},{"key":"10.1016\/j.amepre.2018.09.020_bib0013","unstructured":"Social Security Administration. Actuarial life table. www.ssa.gov\/oact\/STATS\/table4c6.html. Published 2014. Accessed April 6, 2018."},{"issue":"10061","key":"10.1016\/j.amepre.2018.09.020_bib0014","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.amepre.2018.09.020_bib0015","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S1473-3099(17)30170-6","article-title":"Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007\u201308 and 2014\u201315: a qualitative and quantitative assessment","volume":"17","author":"Parikh","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.amepre.2018.09.020_bib0016","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/INF.0b013e318282942f","article-title":"Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease","volume":"32","author":"Granoff","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.amepre.2018.09.020_bib0017","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/INF.0000000000000282","article-title":"The clinical features and long-term sequelae of invasive meningococcal disease in children","volume":"33","author":"Stein-Zamir","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"suppl 2","key":"10.1016\/j.amepre.2018.09.020_bib0018","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.amepre.2018.09.020_bib0019","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1016\/j.vaccine.2014.05.069","article-title":"The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children","volume":"32","author":"Wang","year":"2014","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.amepre.2018.09.020_bib0020","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1093\/cid\/civ028","article-title":"Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study","volume":"60","author":"Sadarangani","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.amepre.2018.09.020_bib0021","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/00006454-199611000-00009","article-title":"Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience","volume":"15","author":"Kirsch","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.amepre.2018.09.020_bib0022","unstructured":"Pfizer. STN 125549-360. PI approved final draft (Trumemba package insert). www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM421139.pdf. Published 2014. Accessed April 23, 2018."},{"key":"10.1016\/j.amepre.2018.09.020_bib0023","unstructured":"GlaxoSmithKline. 125546-189. PI approved final draft (Bexsero package insert). www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM431447.pdf. Published 2015. Accessed April 23, 2018."},{"issue":"7341","key":"10.1016\/j.amepre.2018.09.020_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.324.7341.809","article-title":"Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales","volume":"324","author":"Trotter","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.amepre.2018.09.020_bib0025","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project Databases. www.hcup-us.ahrq.gov\/nisoverview.jsp. Published 2016. Accessed April 23, 2018."},{"issue":"1","key":"10.1016\/j.amepre.2018.09.020_bib0026","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40272-012-0006-0","article-title":"Counting the cost of meningococcal disease","volume":"15","author":"Wright","year":"2013","journal-title":"Pediatr Drugs"},{"issue":"4","key":"10.1016\/j.amepre.2018.09.020_bib0027","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1017\/S0266462300103162","article-title":"The societal costs of severe to profound hearing loss in the United States","volume":"16","author":"Mohr","year":"2000","journal-title":"Int J Technol Assess Health Care"},{"issue":"8","key":"10.1016\/j.amepre.2018.09.020_bib0028","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2106\/JBJS.F.01350","article-title":"Health-care costs associated with amputation or reconstruction of a limb-threatening injury","volume":"89","author":"MacKenzie","year":"2007","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.amepre.2018.09.020_bib0029","series-title":"Measuring Economic Sustainability and Progress","first-page":"493","article-title":"Measuring the stock of human capital for international and intertemporal comparisons","author":"Liu","year":"2014"},{"key":"10.1016\/j.amepre.2018.09.020_bib0030","unstructured":"Mathers CD, Murray CJL, Lopez AD, et al. Estimates of Health Life Expectancy for 191 Countries in the Year 2000: Methods and Results. Geneva, Switzerland: WHO. www.who.int\/choice\/publications\/d_2000_gpe38.pdf?ua=1. Published 2000. Accessed September 27, 2018."},{"issue":"3","key":"10.1016\/j.amepre.2018.09.020_bib0031","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s13300-017-0250-y","article-title":"Cost-effectiveness of liraglutide versus dapagliflozin for the treatment of patients with type 2 diabetes mellitus in the UK","volume":"8","author":"Vega-Hernandez","year":"2017","journal-title":"Diabetes Ther"},{"issue":"8","key":"10.1016\/j.amepre.2018.09.020_bib0032","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1080\/21645515.2017.1316913","article-title":"Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population","volume":"13","author":"Cheng","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.amepre.2018.09.020_bib0033","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40121-014-0053-7","article-title":"Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal vaccine in Japanese children","volume":"4","author":"Shiragami","year":"2014","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.amepre.2018.09.020_bib0034","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1478-7547-11-21","article-title":"A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries","volume":"11","author":"Mart\u00ed","year":"2013","journal-title":"Cost Eff Resour Alloc"},{"issue":"24","key":"10.1016\/j.amepre.2018.09.020_bib0035","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM199012133232402","article-title":"Seizures and other neurologic sequelae of bacterial meningitis in children","volume":"323","author":"Pomeroy","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amepre.2018.09.020_bib0036","unstructured":"European Center for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/1111_SUR_Annual_Epidemiological_Report_on_Communicable_ Diseases_in_Europe.pdf. Published 2011. Accessed April 24, 2018."},{"key":"10.1016\/j.amepre.2018.09.020_bib0037","series-title":"Decision Modeling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"14","key":"10.1016\/j.amepre.2018.09.020_bib0038","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.163.14.1637","article-title":"What is the price of life and why doesn't it increase at the rate of inflation","volume":"163","author":"Ubel","year":"2003","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.amepre.2018.09.020_bib0039","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.amepre.2018.09.020_bib0040","unstructured":"Centers for Disease Control and Prevention (CDC). Meningococcal disease. www.cdc.gov\/meningococcal\/surveillance\/index.html. Published 2018. Accessed April 24, 2018."},{"issue":"suppl 2","key":"10.1016\/j.amepre.2018.09.020_bib0041","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1086\/648963","article-title":"Epidemiological profile of meningococcal disease in the United States","volume":"50","author":"Harrison","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"21","key":"10.1016\/j.amepre.2018.09.020_bib0042","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJM198205273062103","article-title":"On the elicitation of preferences for alternative therapies","volume":"306","author":"McNeil","year":"1982","journal-title":"N Engl J Med"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379718323274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379718323274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T12:14:26Z","timestamp":1550837666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379718323274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0749379718323274"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2018.09.020","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2018.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}